



Critical Path Institute
Employee Conflict of Interest Disclosure

Updated 2/18/2010

Every Critical Path Institute (“Institute”) employee has as a goal and an obligation to act in the best interests of the Institute when performing his or her job. Conflicts can arise from many activities, and the existence of a conflict does not imply wrongdoing on anyone’s part. The Institute’s policy is that all conflicts, whether real, potential, or perceived, must be disclosed annually using this form and whenever a reportable conflict arises.

1. I have a financial interest in an entity developing or marketing health-related products that are regulated by the FDA where the value of the financial interest exceeds \$10,000 and/or 5% ownership:

Joseph Assenzo: Holds shares in at least two pharmaceutical companies. A professional investment counselor manages the investments and makes all decisions regarding trade, sales, and transfers. Employee does not participate in investment decisions; receives periodic reports.

Louis Kirby: Warrants in Provista Life Sciences.

Wayne Peate: Retirement fund invests in several stocks that may include health related companies. I do not actively manage those investments. Family member manages own stock portfolio that includes shares in AMGEN, Johnson and Johnson, Syngenta and Novartis, all pharmaceutical companies.

2. I have a financial interest in an entity developing or marketing health-related products regulated by the FDA where the value of that financial interest cannot be readily determined (for example, stock that is not publicly traded):

Louis Kirby: Provista Life Science warrants – unclear value.

Ralph Martel: As a result of my previous employment, I own founders' shares, common stock, preferred stock, and warrants of privately-held High Throughput Genomics, Inc. These securities are not publicly traded and the value cannot be readily determined.

Raymond Woosley: (1) Patent for Desbutyl halofantrine that is owned by me and two other inventors. No known value. It is being developed by DBH Pharma, Inc., a corporation that is expected to be a "non-profit." I and two inventors are the only principles in the company and serve as officers. (2) Patent held by Georgetown University and the University of Arizona and is not now licensed to any developer. It is a patent for a process to predict individuals at risk of drug-induced arrhythmia and sudden death, and may create a perceived conflict in my research on drug-induced arrhythmias.

3. I have another financial interest that I believe may interfere with, or be perceived to interfere with, my ability to act solely in the best interests of the Institute:

Louis Kirby: Consulting arrangement with Neuraltus, a pharmaceutical company, and Medavante, a service provider for clinical trials.

Wayne Peate: I serve as a principal investigator for a stage O clinical trial with sanofi-aventis, a pharmaceutical company.

4. I have a proprietary interest in some aspect of the Institute's work, such as a patent, trademark, copyright, or licensing agreement:

NONE

5. I am an executive or director of an entity developing or marketing health-related products regulated by the FDA:

Raymond Woosley: Patent for Desbutyl halofantrine that is owned by me and two other inventors. No known value. It is being developed for treatment of malaria by DBH Pharma, Inc., a corporation that is expected to be a "non-profit." I and two inventors are the only principles in the company and serve as officers.